Venclexta8/venetoclax + LDAC New AML ≥75 y or unfit* 63-90 82 54 26 28 6 Median, 10.1 mo Tibsovo61/ivosidenib New AML ≥75 y or unfit* with IDH1MUT 64-87 34 42 30 12 (CRh) N/A N/A —, not available; AML MRC, AML with myelodysplasia-related changes; CR, complete remissi...
Myself and another educator recently developed and began implementing a Retention and Success Nursing Program. These Grant Funded positions were create to help the pass rate of Nursing School and pass the3 NCLEX. Identifying the areas of weakness must occur early so help can begin. Study and Te...